GSK, IDI agree to five-year research partnership

NEW YORK British-American drug manufacturer GlaxoSmithKline and the Immune Disease Institute will work together in immuno-inflammation research under a five-year agreement, they announced Tuesday.

In a deal worth $25 million, GSK and IDI will develop joint grant proposals in targeted research areas. As world-class immunologists work together, GSK will receive the right of first negotiation on a substantial number of new technologies that IDI scientists develop. The agreement will be anchored through GSK’s Immuno-Inflammation Center of Excellence in Drug Discovery II.

Based in Boston, the IDI is a non-profit corporation affiliated with the Harvard Medical School that does immunology research. Despite its affiliation, it is independent of Harvard.